NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Norris SL, Carson S, Thakurta S, et al. Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet]. Portland (OR): Oregon Health & Science University; 2008 Aug.

Cover of Drug Class Review: Thiazolidinediones

Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].

Show details

Appendix BExcluded active-control trials

  1. Aljabri, K., Kozak, S. E., Thompson, D. M. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am. J. Med. 2004; 116 (4):230–5. Excluded due to wrong outcome.
  2. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17 (1):7–12.
  3. Ceriello, A., Johns, D., Widel, M., Eckland, D. J., Gilmore, K. J., Tan, M. H. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28 (2):266–72. Excluded due to wrong outcome.
  4. Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., Schneider, R. L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. Clin. Ther. 2000; 22 (12):1395–409. Excluded due to wrong outcome.
  5. Goke, B., German Pioglitazone Study, G. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treatments in Endocrinology 2002; 1 (5):329–36. Excluded due to wrong outcome.
  6. Jovanovic, L., Hassman, D. R., Gooch, B., Jain, R., Greco, S., Khutoryansky, N., Hale, P. M. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004; 63 (2):127–34. Excluded due to wrong publication type.
  7. Lawrence, J. M., Reid, J., Taylor, G. J., Stirling, C., Reckless, J. P. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27 (1):41–6. Excluded due to wrong outcome.
  8. McCluskey, D., Touger, M. S., Melis, R., Schleusener, D. S., McCluskey, D. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin. Ther. 2004; 26 (11):1783–90. Excluded due to wrong outcome.
  9. Nagasaka, S., Abe, T., Kawakami, A., Kusaka, I., Nakamura, T., Ishikawa, S., Saito, T., Ishibashi, S. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med 2002; 19 (4):347–8. Excluded due to wrong study design.
  10. Nakamura, T., Ushiyama, C., Osada, S., Shimada, N., Ebihara, I., Koide, H. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes. Ren. Fail. 2001; 23 (6):863–4. Excluded due to wrong outcome.
  11. Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., Festa, A., Tan, M. H. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88 (4):1637–45. Excluded due to wrong outcome.
  12. Poulsen, M. K., Henriksen, J. E., Hother-Nielsen, O., Beck-Nielsen, H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26 (12):3273–9. Excluded due to wrong outcome.
  13. Ramachandran, A., Snehalatha, C., Salini, J., Vijay, V. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. J. Assoc. Physicians India 2004; 52:459–63. Excluded due to wrong outcome.
  14. Tan, M. H., Johns, D., Glazer, N. B. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin. Chem. 2004; 50 (7):1184–8. Excluded due to wrong outcome.
  15. Tan MH, Baksi A, Krahulec B, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. Mar 2005;28(3):544–550.
  16. Tiikkainen, M., Hakkinen, A. M., Korsheninnikova, E., Nyman, T., Makimattila, S., Yki-Jarvinen, H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53 (8):2169–76. Excluded due to wrong outcome.
  17. Viberti, G., Kahn, S. E., Greene, D. A., Herman, W. H., Zinman, B., Holman, R. R., Haffner, S. M., Levy, D., Lachin, J. M., Berry, R. A., Heise, M. A., Jones, N. P., Freed, M. I. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25 (10):1737–43. Excluded due to wrong outcome.
  18. Watanabe, I., Tani, S., Anazawa, T., Kushiro, T., Kanmatsuse, K. Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract 2005; 68 (2):104–10. Excluded due to wrong outcome.
  19. Yang, J., Di, F., He, R., Zhu, X., Wang, D., Yang, M., Wang, Y., Yuan, S., Chen, J. Effect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. Chin. Med. J. 2003; 116 (5):785–7. Excluded due to wrong publication type.
  20. Yosefy, C., Magen, E., Kiselevich, A., Priluk, R., London, D., Volchek, L., Viskoper, R. J., Jr. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J. Cardiovasc. Pharmacol. 2004; 44 (2):215–22. Excluded due to wrong outcome.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10738

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...